培美曲塞-NCCN-宫颈癌.pdf

Available online at Gynecologic Oncology 110 (2008) 65 – 70 /locate/ygyno Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group David Scott Miller a,⁎, John A. Blessing b , Diane C. Bodurka c , Albert J. Bonebrake d , John O. Schorge a a University of Texas Southwestern Medical Center at Dallas, USA b Gynecologic Oncology Group Statistical and Data Center; Roswell Park Cancer Institute, Buffalo, NY, USA c The University of Texas; M.D. Anderson Cancer Center, USA d Cancer Research for the Ozarks, Springfield, MO, USA Received 12 February 2008 Available online 5 May 2008 Abstract Objective. To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity. Methods . A multicenter Phase II trial was conducted by the Gynecologic Oncology Group (GOG). Patients must have had advanced or recurrent measurable carcinoma of the cervix, and failed one prior chemotherapy regimen. Pemetrexed at a dose of 900 mg/m2 was to be administered as an IV infusion over 10 min every 21 days. Re